



HUTCHISON CHINA MEDITECH LTD

**Hutchison China MediTech Limited (“Chi-Med”)
(AIM: HCM)**

Director’s Shareholding

London: Friday, 25 June 2010: Chi-Med was informed on 24 June 2010 that Professor Christopher Huang, Independent Non-executive Director of Chi-Med, purchased 2,475 ordinary shares of US\$1.00 each in Chi-Med (the “Shares”) at a price of GBP3.20 each on 22 June 2010.

Following this purchase, Professor Huang is beneficially interested in 2,475 Shares, representing approximately 0.005% of the current issued share capital of Chi-Med.

Ends

Enquiries

Chi-Med

Christian Hogg, CEO

Telephone: +852 2121 8200

Citigate Dewe Rogerson

Anthony Carlisle

David Dible

Telephone: +44 (0) 20 7638 9571

Mobile: +44 (0) 7973 611 888

Mobile: +44 (0) 7967 566 919

Lazard & Co., Limited

Paul Gismondi

Nick Fowler

Telephone: +44 (0) 20 7187 2000

About Chi-Med

Chi-Med is the holding company of a pharmaceutical and healthcare group based primarily in China and was admitted to trading on the Alternative Investment Market of the London Stock Exchange in May 2006. It is focused on researching, developing, manufacturing, and selling pharmaceuticals and health oriented consumer products.

Chi-Med is majority owned by Hutchison Whampoa Limited, an international company listed on the Main Board of The Stock Exchange of Hong Kong Limited.